SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-21-000045
Filing Date
2021-12-20
Accepted
2021-12-20 16:23:39
Documents
15
Period of Report
2021-12-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20211220.htm   iXBRL 8-K 39298
2 EX-99.1 pressrelease-12202021.htm EX-99.1 70199
6 SUMMIT LOGO image_1.jpg GRAPHIC 8727
7 image_2.jpg GRAPHIC 155
  Complete submission text file 0001599298-21-000045.txt   274281

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20211220.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20211220_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20211220_pre.xml EX-101.PRE 12510
9 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20211220_htm.xml XML 11102
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 211505552
SIC: 2834 Pharmaceutical Preparations